Skip to main content

Table 2 Association between basic characteristics and immune cells in the microenvironment

From: Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes

Variable N = 240 CD3+ T cells in the CT CD3+ T cells in the IM CD8+ T cells in the CT CD8+ T cells in the IM Immunoscore
Low High P Low High P Low High P Low High P Low High P
Sex     0.894    1.000    0.355    0.895    0.326
 Male 146 70 (49.3%) 72 (50.7%)   71 (50.0%) 71 (50.0%)   69 (47.3%) 77 (52.7%)   72 (49.3%) 74 (50.7%)   90 (63.4%) 52 (36.6%)  
 Female 94 48 (51.1%) 46 (48.9%)   47 (50.0%) 47 (50.0%)   51 (54.3%) 43 (45.7%)   48 (51.1%) 46 (48.9%)   66 (70.2%) 28 (29.8%)  
Age     0.354    0.015    0.355    0.041    0.011
 < 75 206 98 (48.5%) 104 (51.5%)   94 (46.5%) 108 (53.3%)   100 (48.5%) 106 (51.5%)   97 (47.1%) 109 (52.9%)   127 (62.9%) 75 (37.1%)  
 ≥75 34 20 (58.8%) 14 (41.2%)   24 (70.6%) 10 (29.4%)   20 (58.8%) 14 (41.2%)   23 (67.6%) 11 (32.3%)   29 (85.3%) 5 (14.7%)  
Location     0.464    0.661    0.312    0.014    0.020
 Right 66 35 (54.7%) 29 (45.3%)   34 (53.1%) 30 (46.9%)   37 (56.1%) 29 (43.9%)   42 (63.6%) 24 (37.4%)   50 (78.1%) 14 (21.9%)  
 Left 174 83 (48.3%) 89 (51.7%)   84 (48.8%) 88 (51.2%)   83 (47.7%) 91 (52.3%)   78 (44.8%) 96 (55.2%)   106 (61.6%) 66 (38.4%)  
Pathological differentiation     1.000    1.000    0.580    0.580    0.883
 Poor 77 38 (49.4%) 39 (50.6%)   39 (50.6%) 38 (49.4%)   36 (46.8%) 41 (53.2%)   36 (46.8%) 41 (53.2%)   50 (64.9%) 27 (35.1%)  
 Moderate and well 163 80 (44.7%) 79 (55.3%)   79 (49.7%) 80 (50.3%)   84 (51.3%) 79 (48.7%)   84 (51.3%) 79 (48.7%)   106 (66.7%) 53 (33.3%)  
T stage     0.480    0.672    0.034    0.572    0.453
 T1 + T2 + T3 154 75 (49.7%) 76 (50.3%)   76 (50.3%) 75 (49.7%)   82 (51.9%) 72 (48.1%)   72 (46.8%) 82 (53.2%)   102 (67.5%) 49 (32.5%)  
 T4 74 40 (54.8%) 33 (44.6%)   39 (61.9%) 34 (38.1%)   28 (37.8%) 46 (62.2%)   38 (51.4%) 36 (48.6%)   45 (61.6%) 28 (38.4%)  
 NA 12                
N stage     0.060    0.080    0.566    0.774    0.221
 No 73 31 (43.7%) 40 (56.3%)   32 (45.1%) 39 (54.9%)   32 (43.8%) 41 (56.2%)   32 (43.8%) 41 (56.2%)   42 (59.2%) 29 (40.8%)  
 N1 + N2 141 80 (57.6%) 59 (42.4%)   81 (58.2%) 58 (41.8%)   68 (48.2%) 73 (51.8%)   65 (46.1%) 76 (53.9%)   95 (68.3%) 44 (31.7%)  
 NA 26                
M stage     0.328    0.102    0.337    0.749    0.606
 M0 49 27 (57.4%) 20 (42.6%)   29 (61.7%) 18 (38.3%)   21 (42.9%) 28 (57.1%)   26 (53.1%) 23 (46.9%)   33 (70.2%) 14 (29.88%)  
 M1 191 91 (47.6%) 98 (52.4%)   89 (47.1%) 100 (62.9%)   99 (51.8%) 92 (48.2%)   94 (49.2%) 97 (50.8%)   123 (65.1%) 66 (34.9%)  
MS     0.429    1.000    0.682    1.000    1.000
 MSS 158 73 (47.4%) 81 (52.6%)   73 (47.4%) 81 (52.6%)   80 (50.6%) 78 (49.4%)   75 (47.5%) 83 (52.5%)   97 (61.4%) 57 (38.6%)  
 MSI 6 4 (66.7%) 2 (33.3%)   3 (50%) 3 (50%)   2 (33.3%) 4 (66.7%)   3 (33.3%) 3 (33.3%)   4 (66.7%) 2 (33.3%)  
 NA 76                
KRAS     0.161    0.470    0.176    0.262    0.103
 W 48 15 (31.9%) 32 (68.1%)   15 (31.9%) 32 (68.1%)   21 (43.8%) 27 (56.2%)   21 (43.8%) 27 (56.2%)   22 (46.8%) 25 (53.2%)  
 M 33 15 (48.4%) 16 (51.6%)   15 (45.5%) 18 (64.5%)   20 (60.6%) 13 (39.4%)   19 (57.6%) 14 (42.4%)   21 (67.7%) 10 (32.3%)  
 NA 159                
  1. CT core of the tumor, IM invasive margin, NA not applicable